New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2013
12:27 EDTTWTR, TXTR, TXT, ANIP, TEVAOn The Fly: Midday Wrap
Stocks on Wall Street were slightly lower at midday following another post-holiday morning marked by a light volume of news and trading. ECONOMIC EVENTS: In the U.S., no major economic data was released. COMPANY NEWS: Shares of Twitter (TWTR) were down over 7% near noon after research firm Macquarie downgraded the stock to Underperform, saying that the shares' recent surge is unjustified. Twitter's stock - which had jumped 40% from December 11 through the close of trading yesterday - has climbed "too far, too fast," though there has been no change in Twitter's fundamentals since that date, Macquarie's analyst contended. MAJOR MOVERS: Among the notable gainers was Textron (TXT), which gained 1.3% after agreeing to acquire fellow aircraft maker Beechcraft for $1.4B in cash. Also advancing were shares of ANI Pharmaceuticals (ANIP), which rose more than 20% after the company acquired 31 previously marketed generic drug products from Teva Pharmaceuticals (TEVA). Among the notable losers was Textura (TXTR), which slid for a second straight session following a Citron Research report yesterday alleging that fraud, collusion and deception were involved in the company's IPO. With Textura down another 5% today, William Blair called the sell-off a buying opportunity. INDEXES: Near midday, the Dow was down 4.41, or 0.03%, to 16,475.47, the Nasdaq was down 7.74, or 0.19%, to 4,159.44, and the S&P 500 was down 0.63, or 0.03%, to 1,841.39.
News For TWTR;TXTR;TXT;ANIP;TEVA From The Last 14 Days
Check below for free stories on TWTR;TXTR;TXT;ANIP;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 7, 2014
12:11 EDTTWTRTwitter acquires Cover, terms not disclosed
Subscribe for More Information
06:49 EDTTWTRWeibo looking to raise over $380M in IPO, NY Times says
SINA's (SINA) Weibo hopes to raise more than $380M in its upcoming IPO and price its shares at $17-$19, Weibo said in its prospectus, according to The New York Times. Known as a "microblog," Weibo has been compared to Twitter (TWTR). Reference Link
April 5, 2014
19:30 EDTTWTRTwitter to launch new ad products, WSJ says
In a push to appease e-commerce companies and mobile-game developers, Twitter is planning to debut 15 types of new ad products and ways to target users over the coming six months, says the Wall Street Journal, citing sources. The first group of new adds will be released in a few weeks and will include a product that encourages users to download apps through Twitter, added the Wall Street Journal. Reference Link
April 4, 2014
16:00 EDTTWTROptions Update; April 4, 2014
iPath S&P 500 VIX Short-Term Futures up 89c to 41.88. Option volume leaders: AAPL C P NFLX LNG BAC INTC TSLA TWTR according to Track Data.
11:31 EDTTWTRStocks with call strike movement; JCP TWTR
Subscribe for More Information
10:45 EDTTEVAMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
April 3, 2014
16:00 EDTTWTROptions Update; April 3, 2014
Subscribe for More Information
15:28 EDTTWTRTwitter introduces Vine message service
Subscribe for More Information
14:30 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
14:28 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
12:37 EDTTWTRTwitter downside accelerates, levels to watch
Subscribe for More Information
11:55 EDTTWTRStocks with call strike movement; JCP TWTR
Subscribe for More Information
10:53 EDTTWTRTwitter ban lifted by Turkey, official says, Reuters reports
Subscribe for More Information
07:44 EDTTWTRTurkey court orders Erdogan government to remove Twitter ban, Bloomberg says
Subscribe for More Information
April 2, 2014
16:09 EDTTWTRTwitter heads for test of the $45 area, levels to watch
Subscribe for More Information
13:50 EDTTWTRTwitter heads for test of the $45 area, levels to watch
The stock is down 3% at time of writing to $45.54. At that price the shares are back to where they first met resistance in November of last year following its trading debut which was not breached until December, culminating in a sharp ride into the $70s. A break below $45 would be price bearish on a technical basis, with the life low at $38.80 as the major stop on the downside. Resistance is at $46.98, the prior day close.
11:48 EDTTEVATeva price target raised to $66 from $57 at Standpoint Research
Subscribe for More Information
10:00 EDTTXTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:01 EDTTWTRTwitter user engagement high, says MKM Partners
Subscribe for More Information
07:27 EDTTXTTextron resumed with an Overweight at JPMorgan
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use